138 related articles for article (PubMed ID: 16062072)
1. Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Tsai JY; Iannitti D; Berkenblit A; Akerman P; Nadeem A; Rathore R; Harrington D; Roye D; Miner T; Barnett JM; Maia C; Stuart K; Safran H
Am J Clin Oncol; 2005 Aug; 28(4):329-33. PubMed ID: 16062072
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
Evans D; Miner T; Iannitti D; Akerman P; Cruff D; Maia-Acuna C; Harrington D; Habr F; Chauhan B; Berkenblit A; Stuart K; Sears D; Kennedy T; Safran H
Cancer Invest; 2007 Sep; 25(6):445-8. PubMed ID: 17882656
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Giordano KF; Jatoi A; Stella PJ; Foster N; Tschetter LK; Alberts SR; Dakhil SR; Mailliard JA; Flynn PJ; Nikcevich DA;
Ann Oncol; 2006 Apr; 17(4):652-6. PubMed ID: 16497828
[TBL] [Abstract][Full Text] [Related]
5. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Goel G; Jauhri M; Negi A; Aggarwal S
Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Tebbutt NC; Price TJ; Ferraro DA; Wong N; Veillard AS; Hall M; Sjoquist KM; Pavlakis N; Strickland A; Varma SC; Cooray P; Young R; Underhill C; Shannon JA; Ganju V; Gebski V
Br J Cancer; 2016 Mar; 114(5):505-9. PubMed ID: 26867157
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
8. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Di Lauro L; Vici P; Belli F; Tomao S; Fattoruso SI; Arena MG; Pizzuti L; Giannarelli D; Paoletti G; Barba M; Sergi D; Maugeri-Saccà M
Gastric Cancer; 2014 Oct; 17(4):718-24. PubMed ID: 24318671
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
Lorenzen S; Duyster J; Lersch C; von Delius S; Hennig M; Bredenkamp R; Peschel C; Lordick F
Br J Cancer; 2005 Jun; 92(12):2129-33. PubMed ID: 15942631
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Rosati G; Bilancia D; Germano D; Dinota A; Romano R; Reggiardo G; Manzione L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi128-32. PubMed ID: 17591806
[TBL] [Abstract][Full Text] [Related]
13. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Czito BG; Kelsey CR; Hurwitz HI; Willett CG; Morse MA; Blobe GC; Fernando NH; D'Amico TA; Harpole DH; Honeycutt W; Yu D; Bendell JC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1002-7. PubMed ID: 17197129
[TBL] [Abstract][Full Text] [Related]
14. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
15. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Oka M; Fukuda M; Nagashima S; Fukuda M; Kinoshita A; Soda H; Doi S; Narasaki F; Suenaga M; Takatani H; Nakamura Y; Kawabata S; Tsurutani J; Kanda T; Kohno S
Cancer Chemother Pharmacol; 2001 Dec; 48(6):446-50. PubMed ID: 11800024
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
19. A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3).
Gollins S; Massalha S; Mullard A; Williams RM; Lloyd A; Morris J; Garcia-Alonso A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):409-417. PubMed ID: 29573846
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Schultheis B; Riebeling J; Allali M; Bergmann U; Kummer G; Sendler U; Tannapfel A; Sendler A; Strumberg D
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):451-2. PubMed ID: 20557841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
